Work

Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer

Year: 2013

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdt395

Authors: G.S. Falchook, S.L. Moulder, J.J. Wheler, Y. Jiang, C.C. Bastida, R. Kurzrock

Institutions: The University of Texas MD Anderson Cancer Center, University of California San Diego, Moores Cancer Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: GlaxoSmithKline, National Institutes of Health, Genentech, National Cancer Institute, National Center for Advancing Translational Sciences

Awards: Center for Clinical and Translational Sciences (CCTS), G2536447875, Paul Calabresi Clinical Oncology Award

OpenAlex ID: W2131043872

FWCI: 2.141

Cites: 31

Cited by: 32

Related to: 10